Observational studyBMJ open2025
Association between adjusted atherogenic index of plasma and major adverse cardiovascular events after percutaneous coronary intervention in patients with STEMI: a prospective observational study in China.
Observational study in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma Atherogenic Index Predicts Malignant Arrhythmias in Non-STElevation Myocardial Infarction.The Eurasian journal of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe atherogenic index of plasma (AIP) has been reported as a biomarker for cardiovascular disease risks and clinical outcomes. However, few studies have investigated the relationship between the AIP and major adverse cardiovascular events (MACEs) after percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).
designProspective observational study.
settingData were collected from consecutive patients with STEMI who received PCI at Fuyang People's Hospital from January 2023 to March 2024. PATIENTS: A total of 334 patients with STEMI who underwent PCI. The adjusted AIP (aAIP) was calculated using the following formula: aAIP=log ((triglyceride/high-density lipoprotein cholesterol × 100). The patient population was divided into four groups based on the aAIP quartiles. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was MACEs, and the secondary outcomes included all-cause mortality, all-cause readmission and unplanned readmission as individual endpoints.
resultsAmong 334 eligible patients, 68 (20.36%) experienced MACEs during a median follow-up of 8.70 months. After adjusting for confounders, continuous aAIP was positively correlated with MACEs in all three models. Patients in Q3 and Q4 had significantly higher MACE risks than Q1 (p<0.001 for each model), but no difference was observed between Q1 and Q2 (p>0.05 for each model). Compared with Q1, Q4 had significantly increased all-cause mortality risk (Model 2: HR=12.72, 95% CI 1.39 to 76.44 and Model 3: HR=16.18, 95% CI 1.66 to 117.50). All-cause readmission risk was also higher in Q3 and Q4 (Model 3: Q3: HR=2.242, 95% CI 1.043 to 4.818, p=0.039 and Q4: HR=5.378, 95% CI 2.557 to 11.314, p<0.001). Kaplan-Meier curves showed that higher aAIP was associated with increased risks of MACEs, all-cause readmission and unplanned readmission (all log-rank p<0.0001), but not all-cause mortality (log-rank p=0.1534). No significant interactions between subgroups and the aAIP were observed (p>0.05 for interaction).
conclusionsHigher aAIP was significantly associated with increased risks of MACEs, all-cause readmission and unplanned readmission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.